XOMA 052
Sponsors
XOMA (US) LLC, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), University of Zurich
Conditions
AutoinflammatoryBehcet's DiseaseDiabetes Mellitus Type 1Muckle Wells SyndromeRheumatoid ArthritisType 1 DiabetesType 2 DiabetesType 2 Diabetes Mellitus
Phase 1
Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Type 2 Diabetes Mellitus
CompletedNCT00513214
Start: 2007-07-31End: 2010-02-28Updated: 2011-10-04
Single-dose, Dose-escalation Study of Safety, PK, and Preliminary Efficacy of XOMA 052 in Type 2 Diabetes Mellitus
CompletedNCT00541983
Start: 2007-09-30End: 2010-02-28Target: 36Updated: 2010-05-04
A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's Disease
WithdrawnNCT01211977
Start: 2010-08-27End: 2011-04-29Updated: 2017-07-02
Phase 2
Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Active, Stable, Moderate to Severe Rheumatoid Arthritis
SuspendedNCT00777816
Start: 2009-02-28Target: 18Updated: 2015-12-29
Study of the Effects of XOMA 052 on Insulin Production in Subjects With Well Controlled Type 1 Diabetes
CompletedNCT00998699
Start: 2010-02-28End: 2013-08-31Updated: 2014-03-04
Safety and Efficacy of XOMA 052 in Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy
CompletedNCT01066715
Start: 2010-01-31End: 2011-07-31Updated: 2011-10-04
Study of the Safety and Biologic Activity of XOMA 052 in Subjects With Type 2 Diabetes Mellitus
CompletedNCT01144975
Start: 2010-05-31End: 2011-10-31Updated: 2012-05-16
Effects of XOMA 052 on Insulin Production in Type 1 Diabetes
CompletedNCT01788033
Start: 2009-09-30End: 2013-09-30Updated: 2014-02-11